Uptake of 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolates with four or three bridge carbons [compound 1 (C1) and compound 2 (C2), respectively] into solid tumors by the protoncoupled folate transporter (PCFT) represents a novel therapeutic strategy that harnesses the acidic tumor microenvironment. Although these compounds are not substrates for the reduced folate carrier (RFC), the major facilitative folate transporter, RFC expression may alter drug efficacies by affecting cellular tetrahydrofolate (THF) cofactor pools that can compete for polyglutamylation and/or binding to intracellular enzyme targets. Human tumor cells including wild-type (WT) and R5 (RFC-null) HeLa cells express high levels of PCFT protein. C1 and C2 inhibited proliferation of R5 cells 3 to 4 times more potently than WT cells or R5 cells transfected with RFC. Transport of C1 and C2 was virtually identical between WT and R5 cells, establishing that differences in drug sensitivities between sublines were independent of PCFT transport. Steady-state intracellular [ ]5-formyl-THF were depleted in R5 cells compared with those in WT cells, an effect exacerbated by C1 and C2. Whereas C1 and C2 polyglutamates accumulated to similar levels in WT and R5 cells, there were differences in polyglutamyl distributions in favor of the longest chain length forms. In severe combined immunodeficient mice, the antitumor efficacies of C1 and C2 were greater toward subcutaneous R5 tumors than toward WT tumors, confirming the collateral drug sensitivities observed in vitro. Thus, solid tumor-targeted antifolates with PCFT-selective cellular uptake should have enhanced activities toward tumors lacking RFC function, reflecting contraction of THF cofactor pools.
Introduction
Classic antifolates such as methotrexate (MTX) and pemetrexed (PMX), like folate cofactors, have minimal lipid solubility and therefore require specific transport mechanisms to enter mammalian cells. There are three primary folate transporters, including the reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT), and folate receptor (FR) ␣ (Assaraf, 2007; Goldman et al., 2010) . RFC is the predominant transport route for the major circulating folate, 5-methyl tetrahydrofolate (THF), and (6S)-5-formyl THF (5-CHO-THF) in mammalian cells and tissues . RFC also mediates cellular uptake of MTX and is essential to MTX antitumor activity . Impaired RFC function is a major mechanism of MTX resistance in cultured tumor cells selected in vitro (Zhao and Goldman, 2003; Matherly et al., 2007) and in murine leuke-mia cells in vivo (Sirotnak et al., 1981) . Loss of RFC function in clinical specimens has also been reported (Gorlick et al., 1997; Guo et al., 1999; Yang et al., 2003) . RFC transport of cytotoxic antifolates can also be undesirable because RFC is ubiquitously expressed and exhibits a high level of activity at the neutral pH values characterizing most normal tissues . Thus, transport of antifolates by RFC could easily preclude tumor selectivity and cause toxicity to normal tissues.
The novel 6-substituted pyrrolo [2,3-d] pyrimidine thienoyl antifolates with four [compound 1 (C1)] or three [compound 2 (C2)] carbon bridge lengths ( Fig. 2A) represent a new class of antitumor agents that exhibit a lack of significant membrane transport by RFC . Cellular uptake of C1 and C2 by PCFT and FR␣ is efficient and offers a promising new strategy for solid tumor targeting (Anderson and Thwaites, 2010; . Because PCFT functions optimally at acidic pH values (Qiu et al., 2006; Umapathy et al., 2007; , transport of C1 and C2 by PCFT may lead to further enhancement of tumor selectivity owing to the acidic microenvironments of many solid tumors (Helmlinger et al., 1997; Gillies et al., 2002; Anderson and Thwaites, 2010; Webb et al., 2011) . Our previous results established that C1 and C2 are potent inhibitors of tumor cell proliferation both in vitro and in vivo .
For agents such as PMX that are excellent substrates for both RFC and PCFT, loss of RFC has a limited effect on overall activity, because PMX uptake is maintained by PCFT (Zhao et al., 2004c . Paradoxically, RFC loss has been shown to enhance antitumor activity (i.e., collateral sensitivity) of PMX via decreased intracellular THF cofactor pools (Zhao et al., 2004c; Chattopadhyay et al., 2006 Chattopadhyay et al., , 2007 . This response to RFC loss can be further affected by the type and amount of extracellular folate (Zhao et al., 2004b,c; Chattopadhyay et al., 2006 ).
An analogous effect may exist for PCFT-selective substrates such as C1 and C2, although this has never been systematically tested. In this report, we examine the complex interplay between RFC and extracellular reduced folates. Specifically, we investigate the mechanistic ramifications of loss of RFC function on in vitro and in vivo antitumor efficacies of these PCFT-targeted antifolates. Our results strongly imply that levels of folate transport by RFC in tumors are critical determinants of drug efficacy for this novel class of PCFT-selective antitumor agents.
Materials and Methods
Materials. [3Ј,5Ј,7- 3 H]MTX (20 Ci/mmol), [ 3 H]PMX (2.5 Ci/ mmol), [3Ј,5Ј,7,9-3 Supplemental Table 1S .
Cell Lines. The sources and cell culture conditions for assorted human solid tumor cell lines are summarized in Supplemental Table  2S . HeLa cells were obtained commercially. RFC-null R5 HeLa cells were described previously (Zhao et al., 2004b) . R1-11-mock and R1-11-PCFT4 HeLa cells were derived from human RFC (hRFC)-and -null R1-11 cells by stable transfection with pZeoSV2(ϩ) vector (Invitrogen, Carlsbad, CA) only or with hemagglutinin (HA)-tagged hPCFT in pZeoSV2(ϩ), respectively. Characteristics and culture conditions of the engineered HeLa sublines were described previously and are also in Supplemental Table 2S .
Preparation of hRFC HA /pZeoSV2 and Generation of Stable hRFC R5 Transfectants. Full-length hRFC was subcloned using BamHI and XhoI into pZeoSV2(ϩ) in-frame with a C-terminal HA sequence to generate hRFC HA /pZeoSV2. The plasmid was transformed into XL10-Gold ultracompetent cells (Agilent Technologies, Santa Clara, CA) and selected using low-salt LB agar plates containing 25 g/ml phleomycin (Zeocin). Plasmids were isolated and the wild-type (WT) hRFC insert was confirmed by DNA sequencing by Genewiz Corp. (South Plainfield, NJ).
R5 cells were transfected with pZeoSV2 vector control or hRFC HA / pZeoSV2 with Lipofectamine 2000 and Opti-MEM (Invitrogen). After 24 h, the cells were cultured with phleomycin (0.1 mg/ml). Stable clones were selected by plating for individual colonies in the presence of 0.1 mg/ml phleomycin. Colonies were isolated, expanded, and screened for expression of hRFC HA by real-time reverse transcription (RT)-polymerase chain reaction (PCR), Western blotting, and transport assays at pH 7.2 (below). A representative clone (R5-RFC2) was selected for further study. R5 cells transfected with empty pZeoSV2 (R5-mock) were also prepared.
Gel Electrophoresis and Western Blotting. To characterize hPCFT and hRFC protein levels in assorted human solid tumor cell lines and the R5-RFC2 transfectant, plasma membranes were prepared by differential centrifugation and sucrose density centrifugation (Matherly et al., 1991) . Proteins were quantified with the Folin phenol reagent (Lowry et al., 1951) .
Membrane proteins were electrophoresed on 7.5% polyacrylamide gels with SDS (Laemmli, 1970) and electroblotted onto polyvinylidene difluoride membranes (Thermo Fisher Scientific, Waltham, MA) (Matsudaira, 1987) . For detecting total immunoreactive hPCFT and hRFC proteins on polyvinylidene difluoride membranes, hPCFTor hRFC-specific polyclonal antibodies raised in rabbits to carboxyl termini hPCFT or hRFC (Wong et al., 1998; Hou et al., 2012) peptides and an IRDye800CW-conjugated goat anti-rabbit IgG secondary antibody (Rockland Immunochemicals, Gilbertsville, PA) were used. For detecting HA-tagged proteins (i.e., R5-RFC HA ), HA-specific mouse monoclonal antibody (Covance Research Products, Princeton, NJ) and an IRDye800CW-conjugated goat anti-mouse IgG secondary antibody (Rockland Immunochemicals) were used. Membranes were scanned with the Odyssey infrared imaging system. hPCFT and hRFC levels were normalized to levels of Na ϩ /K ϩ -ATPase (Novus Biologicals, Inc., Littleton, CO).
Transport Assays. To assay hPCFT transport in assorted solid tumor cell lines, uptake of 0.5 M [ 3 H]MTX was measured in cell monolayers in 60-mm dishes over 5 min at 37°C. The transport buffer was MES-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , and 5 mM glucose) at pH 5.5 (Zhao et al., 2004b) . Some transport experiments were performed with 20 nM folic acid to exclude cellular uptake by FRs.
The pH-dependent uptake of
in the HeLa sublines was assayed at 37°C in cell monolayers over 2 min at 37°C in 2 ml of "anion-free" HEPESsucrose-Mg ϩ2 buffer (20 mM HEPES and 235 mM sucrose, pH adjusted to 7.14 with MgO) (AFB) (Wong et al., 1997) , HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , and 5 mM glucose, pH 6.8), or in MES-buffered saline, pH 5.5. Transport fluxes were stopped by aspirating the buffer and quenching with excess (Ͼ5 ml) ice-cold Dulbecco's phosphate-buffered saline (DPBS), followed by 3 washes with DPBS. Cellular proteins were solubilized with 0.5 N NaOH and quantified with the Folin phenol reagent (Lowry et al., 1951) . Drug uptake was expressed as picomoles per milligram of protein, calculated from measurements of radioactivity with a scintillation counter and the protein contents of the cell homogenates.
To measure PCFT transport kinetics (K t and V max ) for [ 3 H]C2 in engineered R1-11-PCFT4 HeLa cells, cells were grown in spinner flasks, collected by centrifugation, washed with DPBS, and suspended (at 1.5 ϫ 10 7 cells) in 2 ml of MES-buffered saline at pH 5.5 containing [
3 H]C2 substrate concentrations ranging from 0.04 to 5 M. K t and V max values were determined from Lineweaver-Burk plots. Kinetic constants for C2 were compared with those previously published for R1-11-PCFT4 cells for C1 and PMX .
Real-Time RT-PCR Analysis of RFC, FR␣, and PCFT Transcripts. RNAs were prepared from WT, R5, and R5-RFC2 HeLa cells using TRIzol reagent (Invitrogen). cDNAs were synthesized using random hexamers, RNase inhibitor, and MuLV reverse transcriptase and purified with the QIAquick PCR Purification Kit (QIAGEN, Valencia, CA). Quantitative real-time RT-PCR was performed on a Roche LightCycler 1.2 (Roche Diagnostics, Indianapolis, IN) with gene-specific primers and FastStart DNA Master SYBR Green I Reaction Mix (Roche Diagnostics) (Ge et al., 2007) . Primers are listed in Supplemental Table 3S . Transcript levels for hRFC were normalized to those for glyceraldehyde-3-phosphate dehydrogenase. External standard curves were constructed for each gene of interest using serial dilutions of linearized templates, prepared by amplification from suitable cDNA templates, subcloning into a TA cloning vector (PCR-Topo; Invitrogen), and restriction digestions.
Cell Proliferation Assays. For proliferation assays, WT and the R5 HeLa sublines were cultured in folate-free RPMI 1640 medium, pH 7.2, supplemented with 10% dialyzed fetal bovine serum, 2 mM L-glutamine, and 100 units/ml penicillin/100 g/ml streptomycin (hereafter referred to as "complete folate-free RPMI 1640 medium"), containing 25 nM 5-CHO-THF, for at least 2 weeks before the experiment. For drug inhibition assays, the cells were plated in 96-well culture dishes (2500 cells/well; 200 l/well) in the above medium with a range of drug concentrations; cells were incubated for up to 96 h at 37°C in a CO 2 incubator. Numbers of cells were assayed with Cell Titer Blue cell viability assays (Promega, Madison, WI) with a fluorescent plate reader for determining IC 50 values (drug concentrations that result in 50% loss of cell growth). To test the impact of extracellular folates on the collateral sensitivities of C1 and C2 in the HeLa sublines, some growth inhibition experiments included increasing concentrations (25, 100, and 1000 nM) of 5-CHO-THF. Accumulation of [ 3 H]5-CHO-THF. WT and R5 HeLa sublines were cultured in complete folate-free RPMI 1640 medium supplemented with 0.06 mM adenosine and 0.01 mM thymidine for 5 days before the experiment. Adenosine and thymidine were added to circumvent folate requirements and to maintain cell viability in the absence of exogenous folates. Cells were treated with 0, 25, 100, and 1000 nM [ 3 H]5-CHO-THF (because [ 3 H](6S)-5-CHO-THF was diluted with nonradioactive (6R,S)-5-CHO-THF for these experiments, the actual concentration of (6S) stereoisomer was 12.5, 50, and 500 nM, respectively) for 4 days, followed by three washes with ice-cold DPBS. A control without added [ 3 H]5-CHO-THF (including 0.06 mM adenosine and 0.01 mM thymidine) was incubated in parallel. Cellular proteins were solubilized with 0.5 N NaOH and quantified using the Folin phenol reagent (Lowry et al., 1951 Measurement of C1 and C2 Polyglutamylation. WT and R5 HeLa cells were depleted of folates by growth for 2 weeks in complete folate-free RPMI 1640 medium plus 25 nM 5-CHO-THF. Cells were plated in medium without nucleosides, supplemented with 25 nM 5-CHO-THF, and allowed to adhere overnight. Cells were washed with DPBS and incubated in the same medium, with 25 mM PIPES/25 mM HEPES, pH 6.8, 0.06 mM adenosine, and 1
. After 16 h, cells were washed three times with ice-cold DPBS and scraped into 5 ml of DPBS, pelleted (1500 rpm), and flash-frozen. Polyglutamyl and unmetabolized drug forms were extracted and levels were quantified by HPLC . Cellular proteins were quantified with the Folin phenol reagent (Lowry et al., 1951) . Polyglutamyl and parent drug forms were normalized to cellular proteins and are expressed as picomoles per milligram of cell protein.
In Vivo Efficacy Study of C1 and C2 in WT and R5 HeLa Xenografts. Cultured WT and R5 HeLa cells were implanted subcutaneously (ϳ10 7 cells/flank) to establish a solid tumor xenograft model (passage 0) in female ICR SCID mice (National Institutes of Health DCT/DTP Animal Production Program, Frederick, MD). The mice were supplied food and water ad libitum. Study mice were maintained on a folate-deficient diet (TD.00434; Harlan Teklad, Madison, WI) starting 18 days before tumor implant to ensure that serum folate levels would approximate those of humans before the start of therapy . This design is analogous to those previously published by others (Alati et al., 1996; Gibbs et al., 2005) .
For the efficacy trial, the experimental animals were pooled, divided into groups (4 mice/group), and implanted bilaterally subcutaneously with 30-to 60-mg tumor fragments (from passage 3) using a 12-gauge trocar. Chemotherapy began on day 3 after tumor implantation, when the number of cells was between 10 7 and 10 8 cells (below the limit of palpation). An organic solvent (ethanol, 5% v/v), carrier (Tween 80, 1% v/v), and sodium bicarbonate (0.5% v/v) were used to effect solubilization of C1 and C2. Injection volumes were 0.2 ml i.v. Tumors were measured with a caliper two to three times weekly. Mice were sacrificed when cumulative tumor burdens reached 1500 mg. Methods of protocol design, drug treatments, toxicity evaluation, and data analysis were described previously (Corbett et al., 1997 (Corbett et al., , 1998 Polin et al., 1997 Polin et al., , 2011 . Experimental parameters as qualitative and quantitative end points to assess antitumor activities include T/C as a percentage (see legend to Table  1 for further details) and T Ϫ C (tumor growth delay) [where T is the median time in days required for the treatment group tumors to reach a predetermined size (e.g., 1000 mg) and C is the median time in days for the control group tumors to reach the same size; tumorfree survivors are excluded from these calculations] and tumor cell kill [log 10 cell kill total (gross) ϭ (T Ϫ C)/(3.32)(Td), where (T Ϫ C) is the tumor growth delay, as described above, and Td is the tumor volume doubling time in days, estimated from the best fit straight line from a log-linear growth plot of control group tumors in exponential growth (100-800 mg)]. The day of tumor implant was day 0. For comparison of antitumor activities with standard agents or between tumors, log 10 kill values were converted to an arbitrary activity rating (Corbett et al., 1997) . With the exception of the xenograft model, these methods are essentially identical to those described previously .
Statistical Analysis. Statistical analyses were performed with GraphPad Instat 4.0.
Results

Expression and Function of hRFC and hPCFT in
Human Solid Tumor Cell Lines. We previously measured substantial levels of hPCFT transcripts by real-time RT-PCR in 52 of 53 human solid tumor cell lines of different origins (e.g., breast, prostate, ovarian, and others) . As an extension of this work, we measured levels of hPCFT proteins for 10 of the tumor cell lines (HepG2, Hep3B, H596, CRL5810, H2595, HCT15, Caco-2, DU145, MDA-MB 321, and SK-MEL5) (Supplemental Table 2S ). We also analyzed four HeLa sublines, including WT and hRFC- null R5 cells, both of which express hPCFT, and two HeLa sublines derived from hRFC-and hPCFT-null R1-11 cells including R1-11-mock (hereafter, R1-11) and R1-11-PCFT4 (R1-11 cells stably transfected with hPCFT) cells. For each cell line, plasma membrane proteins were separated by SDS-PAGE and immunoblotted with hPCFT-specific antibodies. Levels of heterogeneously glycosylated hPCFT proteins detected by Western blotting (Fig. 1A) paralleled those of hPCFT transcripts . hPCFT proteins were detected in all tumor cell lines except for the parental R1-11 cells.
Functional validation of hPCFT expression in the solid tumor cell lines was established by transport assays with [ 3 H]MTX (0.5 M, 5 min) at pH 5.5 (Fig. 1B) Fig. 2A) were potent (nanomolar) inhibitors of proliferation in cells engineered to express hPCFT in the absence of hRFC or FRs , suggesting that C1 and C2 are substrates for hPCFT-mediated cellular uptake. In engineered cell lines, C1 and C2 seemed to be poorly transported by hRFC . Both analogs induced current at Ϫ90 mV and pH 5.5 in Xenopus laevis oocytes microinjected with hPCFT cRNAs, and both were competitive inhibitors of [ 3 H]MTX transport in hPCFT transfectants from pH 5.5 to pH 6.8 ). Transport of [ 3 H]C1 by hPCFT was directly demonstrated in R1-11-PCFT4 cells .
To confirm hPCFT transport of C2, R1-11-PCFT4 cells were incubated with [ 3 H]C2 (0.5 M, 5 min, 37°C) at pH 5.5 and 6.8 in the presence and absence of unlabeled C1 (10 M) as a competitive inhibitor. Transport was detected at a ϳ4-fold higher level at pH 5.5 than at pH 6.8, and at both pHs uptake was substantially inhibited in the presence of unlabeled C1 (Fig. 2B) . These results establish that C2, like its 4-carbon chain homolog, C1, is a bona fide substrate for membrane transport by hPCFT. Transport kinetic parameters for C2 with R1-11-PCFT4 cells at pH 5.5 are summarized in Supplemental Table 4S . K t and V max values for C2 were similar to those previously reported for C1 and PMX .
Transport and Membrane Expression of hPCFT and hRFC in WT and R5 HeLa Sublines. Although C1 and C2 are not RFC transport substrates , RFC levels could nonetheless have a marked impact on the antiproliferative effects of these agents, via expansion or contraction of intracellular THF cofactor pools. Thus, RFC levels or ratios of PCFT to RFC transport might effectively predict the antitumor potencies of these prototypical PCFT-targeted antifolates. This result could be further affected by varying concentrations of extracellular THF cofactors. 
Downloaded from
To explore this concept, we used WT and R5 HeLa cells, which express comparable levels of hPCFT with or without hRFC ( Figs. 1 and 3A; Supplemental Fig. 1SA ). R5 cells are resistant to MTX (Fig. 5A) because of a genomic deletion that results in loss of hRFC (Zhao et al., 2004a) . MTX resistance is completely reversible upon transfection with WT hRFC (R5-RFC2 cells), which restores hRFC transport (Supplemental Fig. 1SB ), confirming that loss of hRFC transport causes the resistant phenotype.
Whereas [ 3 H]MTX (0.5 M) transport by hPCFT at pH 5.5 was nearly identical for WT and R5 HeLa cells (Fig. 3B) , MTX uptake in R5 cells in AFB at pH 7.2 was decreased ϳ3-fold compared with that in WT cells (Fig. 3C) , consistent with the loss of hRFC. Ratios of MTX transport at pH 5.5 (PCFT) to pH 7.2 (RFC) for R5 and WT cells were ϳ11 and ϳ3, respectively (Fig. 3D) (Fig. 3, B and C) . For all compounds and both cell lines, transport by hPCFT over hRFC predominated, because uptake showed the characteristic pH dependence for PCFT with the highest levels at pH 5.5. Although there were slight differences in initial rates of uptake of the various analogs at pH 5.5, these were not statistically significant. Furthermore, there were no obvious differences in membrane transport of the individual analogs between WT and R5 HeLa cell lines.
Impact of hRFC and Extracellular Folate on Antitumor Activities of C1 and C2. (6S)-5-CHO-THF is poorly transported by PCFT at neutral pH and is less effective in supporting proliferation of PCFT-expressing cells (without RFC) than RFC-expressing cells (without PCFT) . Thus, loss of hRFC in R5 cells would be predicted to contract intracellular pools of reduced folates derived from 5-CHO-THF, compared with those in WT HeLa cells (Zhao et al., 2004b; Chattopadhyay et al., 2006) . This effect may be exacerbated in the presence of high-affinity hPCFT-selective substrates, which could further restrict the modest levels of THF cofactor uptake via PCFT through direct competition.
To examine these possibilities, folate-depleted WT, R5, and R5-RFC2 cells were cultured in 25, 100, or 1000 nM for three independent experiments. Although there were slight differences in initial rates of uptake for C1 and C2 for both WT and R5 HeLa cells in B, these were not statistically significant (p Ͼ 0.1), consistent with the very modest differences in transport kinetics between these drugs (Supplemental Table 4S ). 3 H]5-CHO-THF accumulations were preserved at these concentrations between R5 and R5-RFC2 cells (Fig. 4A) .
Impact of RFC on PCFT-Targeted
We measured proliferation of WT and R5 HeLa cells grown in 25 nM 5-CHO-THF in the presence of a range of concentrations (0-1000 nM) of the PCFT-selective antifolates C1
and C2 for comparison with MTX, lometrexol (LMX), raltitrexed (RTX), and PMX, classic antifolates that are transported by both RFC and PCFT (Goldman et al., 2010; Kugel Desmoulin et al., 2010 and with N ␣ -(4-amino-4-deoxypteroyl)-N ␦ -hemiphthaloyl-L-ornithine (PT523), which is transported by RFC but not by PCFT (Zhao and Goldman, 2007; Kugel Desmoulin et al., 2010 (Fig. 5A ; Supplemental Table 5S ). Similar to published results (Zhao et al., 2004c) , R5 (and R5-mock transfected) cells were substantially resistant to PT523 compared with WT (Ͼ 213-fold) and R5-RFC2 (Ͼ 303-fold) cells. Furthermore, R5 cells were resistant (5-to 14-fold) to MTX, LMX, and RTX compared with WT HeLa cells. For PMX, IC 50 values for WT and R5 cells were modestly different (IC 50 values of 48.3 and 66.1 nM, respectively). It is noteworthy that hRFC-deficient R5 cells were substantially more sensitive to the PCFT-specific antifolates C1 and C2 than were WT cells (3.6-and 3.2-fold, respectively) and R5-RFC2 transfected cells (3.6-and 8.3-fold, respectively). Although differences in growth inhibitions between R5 and WT cells for C1 and C2 were preserved when the extracellular 5-CHO-THF was increased to 100 nM (4.3-and 15-fold, respectively), the effects of both drugs were effectively abolished when the 5-CHO-THF concentration was increased to 1000 nM (Fig. 5, B and C) .
Because C1 and C2 are high-affinity substrates for PCFT, we hypothesized that these drugs compete with [ 3 H]5-CHO-THF for PCFT uptake, leading to a more severe contraction of the cellular folate pool in R5 cells compared with WT cells than in their absence. Indeed, both C1 and C2 effected a striking dose-dependent decrease in net accumulations of [ 3 H]5-CHO-THF, which were greater in hRFC-null R5 cells than in WT HeLa cells. At 1000 nM C1, levels of [ 3 H]5-CHO-THF accumulation in R5 and WT HeLa cells were 52.9 and 72.9%, respectively, of levels without drug; for C2, the corresponding values were 52.7 and 71.1%, respectively (Fig. 4 , B and C).
Collectively, these results establish that loss of hRFC contributes to a contraction of cellular folate pools, which is exacerbated in the presence of the PCFT-selective analogs C1 and C2. Of importance, decreased intracellular folates were accompanied by markedly increased antiproliferative effects of C1 and C2.
Polyglutamylation of C1 and C2 in WT and R5 HeLa Cells. Analogous to physiologic folates and other classic antifolate drugs such as MTX (Goldman and Matherly, 1985; Shane, 1989; Assaraf, 2007) , C1 is metabolized to polyglutamates (PGs) . Polyglutamylation of C2 has not been assessed previously. Because polyglutamylation of antifolate drugs by folylpolyglutamate synthetase (FPGS) can be regulated by elevated extra-and intracellular folates Zhao et al., 2001) , it seemed possible that the impact of hRFC and cellular THF cofactors on the antiproliferative effects of C1 and C2 may be partly explained in this manner.
To . WT and R5 cells accumulated similar levels of total C1 and C2 drug forms, although there were slight differences in relative accumulations of individual PGs between the cell lines. This difference was most obvious for the longest chain length PGs (PG 5 and PG 6 ) and was somewhat greater for C1 than for C2.
These results establish that 1) both C1 and C2 are excellent substrates for polyglutamylation under conditions that favor their membrane transport by PCFT, 2) net drug accumulation and polyglutamylation of C2 far exceeds that for C1, and 3) the presence or absence of functional RFC manifests at most a modest effect on net C1 and C2 polyglutamate synthesis.
In Vivo Efficacy of C1 and C2 against WT and R5 HeLa Xenografts. To extend our in vitro cell proliferation studies in vivo, we performed in vivo antitumor efficacy studies with 8-week-old female ICR SCID mice implanted with subcutaneous R5 or WT HeLa cells. Mice were maintained ad libitum on a folate-deficient diet, which decreased serum folates to levels approximating those seen in humans. For the efficacy trial, control and drug treatment groups were nonselectively randomized (four mice/group); C1 or C2 was administered intravenously (180 and 32 mg/kg per injection, respectively) on days 3, 7, 14, and 18 after implantation. As reported for other tumor models , C1 and C2 showed substantial efficacies toward R5 and WT HeLa xenografts (Table 1) . Both C1 and C2 showed greater efficacies toward R5 cells (T Ϫ C ϭ 23 days, 3.3 gross log 10 kill for C1; T Ϫ C ϭ 17.5 days, 2.5 gross log 10 kill for C2) than toward WT cells (T Ϫ C ϭ 13 days, 1.9 gross log 10 kill for C1; T Ϫ C ϭ 13 days, 1.9 gross log 10 kill for C2). Differences in C Ϫ T and log 10 kill results between R5 and WT HeLa cells for compound C1 were statistically significant (p ϭ 0.014 and p ϭ 0.0135, respectively). However, differences in these parameters for C2 did not quite reach statistical significance (p ϭ 0.146). The treatment regimens with C1 and C2 were well tolerated with dose-limiting symptoms manifesting as reversible body weight loss.
The results of the in vivo efficacy trial provide proof-of-principle confirmation of our in vitro findings that the antitumor effects of both C1 and C2 are greater in hRFC-deficient R5 cells than in WT cells. Of interest, the impact of loss of hRFC seems to be somewhat greater with C1 than with C2 in vivo.
Discussion
In this study, we expanded on previous reports (Zhao and Goldman, 2007; Goldman et al., 2010; ) that hPCFT may be exploitable for cancer therapy, reflecting unique patterns of hPCFT expression and appreciable transport activity at pH values approximating the tumor microenvironment. We extended our previous findings establishing broad-ranging hPCFT gene expression in a large number of human tumor cell lines to include measurements of hPCFT protein and transport activity. Our results document the fact that hPCFT protein levels are abundantly expressed, accompanying substantial transport activities at pH 5.5. We demonstrated that functional loss of hRFC in R5 cells caused a contraction of total cellular THF cofactor pools derived from 5-CHO-THF, which enhanced both C1 and C2 antitumor activities compared with those in WT cells. Of importance, the reduction in total cellular folate pools in R5 cells was exacerbated in the presence of C1 and C2, through direct competition at hPCFT, which further restricted cellular uptake of exogenous 5-CHO-THF. Efficacies of C1 and C2 toward R5 tumors were also increased compared with those toward WT tumors transplanted into SCID mice with serum folate concentrations approximating those achieved in humans, although this effect seemed to be somewhat greater with C1 than with C2 in vivo. We previously reported that the in vivo efficacy of C2 toward IGROV1 xenografts in SCID mice was less affected by serum folates than that for C1 .
There is ample precedent for an impact of folate pools on antifolate drug efficacy. Indeed, this is the premise of leucovorin rescue from MTX toxicity (Matherly et al., 1987) and of low-dose folic acid protection from LMX toxicity in vivo (Roberts et al., 2000) , whereby elevated extra-and intracellular folates compete at multiple levels to reverse drug activity. In vitro studies have extended these findings to both classic (PMX and LMX) and nonclassic (trimetrexate) antifolates, which inhibit a range of cellular targets Zhao et al., 2001; Goldman et al., 2010) . Furthermore, antifolate drug activities are enhanced by decreased intracellular folates resulting from an hRFC genomic deletion (Zhao et al., 2004b,c; Chattopadhyay et al., 2006) or hRFC mutations (Zhao et al., 2000a) . Conversely, antifolate effects are reduced by increased intracellular folates resulting from impaired efflux of folic acid (Assaraf and Goldman, 1997) or enhanced folic acid influx by a mutant RFC .
Regardless of the underlying mechanism and intracellular drug target involved, markedly decreased total intracellular THF pools can result in collateral sensitivities to antifolates, often in the face of substantially decreased levels of drug uptake (Zhao et al., 2000b (Zhao et al., , 2001 (Zhao et al., , 2004c . The effects of folate levels on antifolate activities could reflect inhibitory effects on drug polyglutamylation (with consequent impact on drug retention and inhibition of folate-dependent enzyme targets) as a result of competitive feedback inhibition at FPGS by high levels of THF cofactor PGs (Nimec and Galivan, 1983; Shane, 1989; Zhao et al., 2001 Zhao et al., , 2004b or increased FPGS activity levels in response to decreased extra-and intracellular folates (Gates et al., 1996) . Furthermore, direct competitive interactions between polyglutamyl folates and antifolates may substantially interfere with drug binding and inhibition at their enzyme targets, as documented for MTX (Matherly et al., 1983) . Changes in drug efflux are also possible, because ABC transporter (ABCG2, ABCC1) levels and/or intracellular distributions have been described in response to folate deprivation (Ifergan et al., 2005) .
In the present study, we found that C1 and C2 membrane transport by PCFT was virtually identical between the hRFC-deficient R5 and WT HeLa cell lines. Total and polyglutamyl accumulations of C1 and C2 during sustained drug exposures were similar between WT and R5 cells, although there were slight differences in distributions of C1 and C2 polyglutamates between the lines. This difference was most pronounced for the longest chain length PGs (PG 5 and PG 6 ) and seemed to be somewhat greater for C1 than C2. By analogy with other classic antifolates (Mendelsohn et al., 1999; Shih and Thornton, 1999) , increased accumulation of long-chain polyglutamyl forms of C1 and C2 in the R5 subline might result in enhanced inhibition of intracellular glycinamide ribonucleotide formyltransferase and de novo purine nucleotide biosynthesis , thus further exacerbating the impact The 8-week-old female NCR SCID mice were implanted bilaterally subcutaneously with 30-to 60-mg tumor fragments by a 12-gauge trocar on day 0. Both tumor studies (WT and R5 HeLa cells) used four mice per group. Median mouse body weights for each experiment were within 2 g and were 19 g (WT) or 19.5 g (R5) HeLa cells at the start of therapy. Chemotherapy was started on day 3 after tumor implantation, when the numbers of cells were small (10 7 -10 8 cells). Day 0 is the day of tumor implant. Median tumor masses were determined (including zeros). To determine the T/C value, the treatment and control groups were measured when the control group tumors reached 1000 mg in size (median of group). T/C is an indication of antitumor effectiveness. T/C Յ42% is considered significant antitumor activity by the Drug Evaluation Branch of the Division of Cancer Treatment (National Cancer Institute). T/C Ͻ10% is considered to indicate highly significant antitumor activity and is the level used to justify a clinical trial if toxicity, formulation, and certain other requirements are met. T/C ϭ 0 indicates very high antitumor activity. Statistical analyses were performed for the differences in T Ϫ C and log 10 kills between WT and R5 HeLa cells for C1 and C2 relative to the median control values for each tumor. Differences in T Ϫ C and log 10 kill results between R5 and WT HeLa cells for compound C1 were statistically significant (P ϭ 0.014 and P ϭ 0.0135, respectively). Whereas these parameters also differed for C2 between the cell lines, these differences did not quite reach statistical significance (P ϭ 0.146). of reduced cellular folate pools in directly competing for binding to this enzyme target. Our results provide proof-of-principle evidence that hRFC levels and function are critical determinants of antitumor activities and in vivo efficacies of PCFT-targeted antifolates that are not themselves RFC substrates. This lack of RFC transport confers tumor selectivity and decreased toxicity to normal tissues for this novel class of agents. Tumor selectivity would be enhanced by substantial levels of hPCFT protein in solid tumors and by acidic pH values characterizing the tumor microenvironment, which favor PCFT over RFC transport . Conversely, at neutral pH values characterizing most normal tissues, RFC transport of reduced folates would be increased, resulting in elevated levels of THF cofactors within cells, which further protect from untoward drug effects. Of course, as suggested in this report, in tumors with sufficiently high hRFC, uptake of THF cofactors by this process will probably occur, even at somewhat acidic pH values. Accordingly, any decrease in hRFC function would serve to augment the inherent antitumor selectivities and increase sensitivities to PCFT-selective antifolates. 
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Dr. Aleem Gangjee (Pittsburgh, PA) H]C2 at pH 6.8 in the presence of adenosine (0.06 mM) and 25 nM 5-CHO-THF for 16 h. Drug metabolites were extracted and analyed by reverse-phase HPLC. Fractions were collected and radioactivity was measured. Details are described in Materials and Methods. Polyglutamates are labeled PG 2 -PG 6 whereas monoglutamyl C2 is labeled as such. WT HeLa -C2
